WHO ICTRP trial
Efficiency and tolerability of 30% new supramolecular salicylic acid for rosacea
ChiCTR-OOH-17012560 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-OOH-17012560 |
|---|---|
| Public title | Efficiency and tolerability of 30% new supramolecular salicylic acid for rosacea |
| Scientific title | Efficacy and skin tolerability of the addition of 30% new supramolecular salicylic acid to Minocycline for erythematotelangiectatic and papulopustular rosacea:A split-face study |
| Primary sponsor | The Second Affliated Hospital of Xi'an Jiaotong University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | Other |
| Countries | China |
| Conditions | rosacea |
| Interventions | experimental group:30% new supramolecular salicylic acid; Minocycline. |
| Registration date | Sep 3, 2017 |
| Target size | experimental group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: